scholarly journals Recent advances in the management and understanding of macular degeneration

F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 519 ◽  
Author(s):  
Sepehr Bahadorani ◽  
Michael Singer
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Vascular Endothelial ◽  
Current Management ◽  
Vegf Inhibitors ◽  
Age Related ◽  
Dry Amd ◽  
Endothelial Growth Factor ◽  
Wet Amd

Current management of age-related macular degeneration (AMD) is directed at intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors for the treatment of wet AMD and supplementation with oral antioxidants for the treatment of dry AMD. In this article, we will review recent clinical trials for the treatment of dry and wet AMD.

scholarly journals The Use of Vascular Endothelial Growth Factor Inhibitors and Complementary Treatment Options in Polypoidal Choroidal Vasculopathy: A Subtype of Neovascular Age-Related Macular Degeneration

2018 ◽  
Vol 19 (9) ◽  
pp. 2611 ◽  
Author(s):  
Kelvin Teo ◽  
Mark Gillies ◽  
Samantha Fraser-Bell
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Macular Degeneration ◽  
Polypoidal Choroidal Vasculopathy ◽  
Age Related Macular Degeneration ◽  
Vascular Endothelial ◽  
Vegf Inhibitors ◽  
Age Related ◽  
Endothelial Growth Factor ◽  
Choroidal Vasculopathy

Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular age-related macular degeneration (AMD; nAMD) which occurs more commonly in Asian populations as compared to Caucasians. PCV and nAMD share pathological mechanisms, including pathological expression of vascular endothelial growth factor (VEGF). The advent of anti-vascular endothelial growth factor (VEGF) revolutionized the treatment of nAMD. Despite being a subtype of nAMD, PCV responds less well to VEGF inhibitors; thus, photodynamic therapy (PDT) in combination with anti-VEGF treatment may be considered. This review aims to summarize the current evidence for the treatment of PCV, especially whether VEGF inhibitors should be used alone or in combination with PDT.

scholarly journals PPAR-αLigands as Potential Therapeutic Agents for Wet Age-Related Macular Degeneration

PPAR Research ◽  
2008 ◽  
Vol 2008 ◽  
pp. 1-5 ◽  
Author(s):  
Marisol del V Cano ◽  
Peter L. Gehlbach
Keyword(s):  
Macular Degeneration ◽  
Immune Modulation ◽  
Age Related Macular Degeneration ◽  
Peroxisome Proliferator ◽  
Vascular Endothelial ◽  
Age Related ◽  
Dry Amd ◽  
Peroxisome Proliferator Activated Receptors ◽  
Endothelial Growth Factor ◽  
Wet Amd

The peroxisome proliferator-activated receptors (PPAR's) are members of the steroid/thyroid nuclear receptor, superfamily of transcription factors. There are currently three known PPAR subtypes,α,β, andγ. The PPARs are now recognized participants in a number of biological pathways some of which are implicated in the pathogenesis of age-related macular degeneration (AMD). These include immune modulation, lipid regulation, and oxidant/antioxidant pathways important to the onset and progression of “dry” AMD, and vascular endothelial growth factor (VEGF) mediated pathways that stimulate choroidal neovascularization (CNV), characteristic of “wet” AMD. PPAR-αis found in retina and also on vascular cells important to formation of CNV. At this time, however, relatively little is known about potential contributions of PPAR-αto the pathogenesis of dry and wet AMD. This review examines current literature for potential roles of PPAR-αin the pathogenesis and potential treatment of AMD with emphasis on prevention and treatment of wet AMD.

TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN EVERYDAY PRACTICE

Retina ◽  
2018 ◽  
Vol 38 (6) ◽  
pp. 1134-1144 ◽  
Author(s):  
Christoph Ehlken ◽  
Thomas Wilke ◽  
Ulrike Bauer-Steinhusen ◽  
Hansjürgen T. Agostini ◽  
Zoran Hasanbasic ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Everyday Practice ◽  
Vascular Endothelial ◽  
Age Related ◽  
Endothelial Growth Factor
Sign in / Sign up

Export Citation Format

Share Document